3 completed, 2 terminated, 1 recruiting, 1 withdrawn. 6 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Camostat Mesylate: new trials by email Literature Review of Camostat Mesylate trials Research Report on Camostat Mesylate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect Camostat for Kidney Protection in Chronic Kidney Disease Camostat Mesylate - Chronic Kidney Disease(CKD) | Phase 2 | Recruiting | Odense University Hospital | 40 | 2024-11-21 | 2025-01-27 |
| Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation Camostat mesylate - Fontan Operation, Protein-Losing Enteropathy | Phase 2 | Completed | Seoul National University Hospital | 19 | 2022-10-03 | 2024-12-03 |
| The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications Camostat Mesylate, Microcrystalline Cellulose, NF - Coagulopathy, Cardiovascular Complication | Phase 1 / Phase 2 | Withdrawn | Yale University | 2021-11-01 | 2022-05-18 | |
| CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients Camostat Mesylate, Placebo - Covid19 | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 70 | 2020-12-03 | 2022-02-10 |
| Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT) Camostat Mesilate, Placebo - COVID-19 | Phase 2 | Completed | Sagent Pharmaceuticals Inc. | 295 | 2020-11-09 | 2022-01-18 |
| A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) Camostat - COVID-19 Infection | Phase 2 | Terminated | Cancer Research UK | 34 | 2020-09-23 | 2023-12-11 |
| ACTIV-2: A Study for Outpatients With COVID-19 bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV) - Coronavirus, Covid19 | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 4044 | 2020-08-19 | 2024-08-02 |
COVID-19 (5) · Coronavirus Infections (2) · Virus Diseases (2) · Albuminuria (1) · Coronaviridae Infections (1) · Hemostatic Disorders (1) · Nidovirales Infections (1) · Pneumonia, Viral (1) · Protein-Losing Enteropathies (1) · Proteinuria (1) · RNA Virus Infections (1) · Renal Insufficiency, Chronic (1) · Respiratory Tract Infections (1) · Severe Acute Respiratory Syndrome (1)
Assistance Publique - Hôpitaux de Paris (1) · Cancer Research UK (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Odense University Hospital (1) · Sagent Pharmaceuticals Inc. (1) · Seoul National University Hospital (1) · Yale University (1)
United States (2) · Argentina (1) · Brazil (1) · Canada (1) · Denmark (1) · France (1) · Guatemala (1) · Mexico (1) · Philippines (1) · Puerto Rico (1) · South Africa (1) · South Korea (1) · United Kingdom (1)
Arya Mani, MD (1) · Claus Bistrup, MD, Professor (1) · David Smith, MD, MAS (1) · Gi Beom B Kim (1) · Kevin Dhaliwal, Professor (1)
PMID 34473343, PMID 34981077, PMID 35713300, PMID 35793677, PMID 35797235, PMID 35995785, PMID 36210483, PMID 36289399, PMID 36301549, PMID 36378539, PMID 36467293, PMID 36661240, PMID 36802755, PMID 37068272, PMID 37099295, PMID 37279602, PMID 37650230, PMID 37650232, PMID 37650233, PMID 37650236, PMID 37855026, PMID 39018444, PMID 39028902, PMID 40227431, PMID 42148571
2023 (1)